| Fexofenadine HCl |
Tablet (Orally Disintegrating) |
II (Paddle) |
50 |
0.001 N HCl |
500 |
5, 10, 15, 30 and 45 |
2008/09/03 |
| Fexofenadine HCl |
Suspension |
II (Paddle) |
50 |
0.001 N HCl |
900 |
10, 20, 30 and 45 |
2008/11/25 |
| Fexofenadine HCl/Pseudoephedrine HCl |
Tablet (Extended Release) |
|
|
Refer to USP |
|
|
2009/04/02 |
| Fezolinetant |
Tablet |
|
|
Refer to FDA's Dissolution Guidance, 2018 |
|
|
2024/08/05 |
| Fidaxomicin |
For Oral Suspension |
|
|
Develop a dissolution method |
|
|
2023/09/15 |
| Fidaxomicin |
Tablet |
|
|
Develop a dissolution method |
|
|
2023/09/15 |
| Finafloxacin |
Otic Suspension |
|
|
Develop a method to characterize in vitro release |
|
|
2016/03/17 |
| Finasteride |
Tablet |
|
|
Refer to FDA's Dissolution Guidance, 2018 |
|
|
2020/07/02 |
| Finasteride; Tadalafil |
Capsule |
|
|
Develop a dissolution method |
|
|
2024/02/05 |
| Finerenone |
Tablet |
II (Paddle) |
75 |
Acetate Buffer, pH 4.5 (for 10 mg strength) and Acetate Buffer, pH 4.5 with 0.1% polysorbate 20 (for 20 mg strength) |
900 |
5, 10, 15, 20 and 30 |
2023/02/09 |
| Fingolimod |
Capsule |
I (Basket) |
100 |
0.1 N HCl with 0.2% SDS (sodium dodecyl sulfate) |
500 |
5, 10, 15, 20 and 30 |
2013/08/15 |
| Fingolimod Lauryl Sulfate |
Tablet, Orally Disintegrating |
II (Paddle) with sinker |
50 |
0.1 N HCl with 0.2% sodium dodecyl sulfate (SDS) |
500 |
5, 10, 15, 20, 25, 30 and 45 |
2023/11/30 |
| Flavoxate HCl |
Tablet |
I (Basket) |
100 |
0.1 N HCl |
900 |
5, 10, 20 and 30 |
2004/01/29 |
| Flecainide Acetate |
Tablet |
|
|
Refer to FDA's Dissolution Guidance, 2018 |
|
|
2020/07/02 |
| Flibanserin |
Tablet |
II (Paddle) |
50 |
McIlvaine Buffer, pH 4.0 [61 mM Citric Acid solution + 77 mM dibasic sodium phosphate solution]. Measure the pH and adjust to 4.0, if necessary. |
900 |
5, 10, 15, 20 and 30 |
2025/05/19 |
| Fluconazole |
Tablet |
|
|
Refer to FDA's Dissolution Guidance, 2018 |
|
|
2020/07/02 |
| Fluconazole (200 mg/5 mL) |
Suspension |
|
|
Develop a dissolution method |
|
|
2023/09/15 |
| Fluconazole (50 mg/5 mL) |
Suspension |
|
|
Develop a dissolution method |
|
|
2023/09/15 |
| Flucytosine |
Capsule |
|
|
Refer to FDA's Dissolution Guidance, 2018 |
|
|
2020/07/02 |
| Fludarabine Phosphate |
Tablet |
|
|
Develop a dissolution method |
|
|
2023/09/15 |